2013, Volume 7, Issue 2
Frontiers of Medicine >> 2013, Volume 7, Issue 2 doi: 10.1007/s11684-013-0267-1
Progress on molecular biomarkers and classification of malignant gliomas
1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China;
2. Beijing Neurosurgical Institute, Beijing 100050, China
Next Previous
Abstract
Gliomas are the most common primary intracranial tumors in adults. Anaplastic gliomas (WHO grade III) and glioblastomas (WHO grade IV) represent the major groups of malignant gliomas in the brain. Several diagnostic, predictive, and prognostic biomarkers for malignant gliomas have been reported over the last few decades, and these markers have made great contributions to the accuracy of diagnosis, therapeutic decision making, and prognosis of patients. However, heterogeneity in patient outcomes may still be observed, which highlights the insufficiency of a classification system based purely on histopathology. Great efforts have been made to incorporate new information about the molecular landscape of gliomas into novel classifications that may potentially guide treatment. In this review, we summarize three distinctive biomarkers, three most commonly altered pathways, and three classifications based on microarray data in malignant gliomas.
Keywords
malignant glioma ; molecular biomarker ; IDH1 ; MGMT ; molecular classification
京公网安备 11010502051620号
